Follow
Dora Dias-Santagata
Dora Dias-Santagata
Harvard Medical School, Massachusetts General Hospital
Verified email at mgh.harvard.edu
Title
Cited by
Cited by
Year
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ...
Science translational medicine 3 (75), 75ra26-75ra26, 2011
36342011
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ...
Cancer cell 17 (1), 77-88, 2010
12222010
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
RB Corcoran, H Ebi, AB Turke, EM Coffee, M Nishino, AP Cogdill, ...
Cancer discovery 2 (3), 227-235, 2012
10942012
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
10872016
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, ...
The oncologist 17 (1), 72-79, 2012
8072012
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ...
Clinical cancer research 19 (15), 4273-4281, 2013
6282013
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
C Montagut, SV Sharma, T Shioda, U McDermott, M Ulman, LE Ulkus, ...
Cancer research 68 (12), 4853-4861, 2008
6142008
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K Ohashi, LV Sequist, ME Arcila, T Moran, J Chmielecki, YL Lin, Y Pan, ...
Proceedings of the National Academy of Sciences 109 (31), E2127-E2133, 2012
5072012
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee, JW Neal, ...
Cancer discovery 5 (7), 713-722, 2015
5002015
Nedd8 on cullin: building an expressway to protein destruction
ZQ Pan, A Kentsis, DC Dias, K Yamoah, K Wu
Oncogene 23 (11), 1985-1997, 2004
4912004
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ...
Annals of Oncology 22 (12), 2616-2624, 2011
4692011
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
PK Brastianos, A Taylor-Weiner, PE Manley, RT Jones, D Dias-Santagata, ...
Nature genetics 46 (2), 161-165, 2014
4542014
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience
LM Sholl, DL Aisner, M Varella-Garcia, LD Berry, D Dias-Santagata, ...
Journal of thoracic oncology 10 (5), 768-777, 2015
4382015
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
RB Corcoran, D Dias-Santagata, K Bergethon, AJ Iafrate, J Settleman, ...
Science signaling 3 (149), ra84-ra84, 2010
4182010
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ...
EMBO molecular medicine 2 (5), 146-158, 2010
4092010
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
RB Corcoran, KA Cheng, AN Hata, AC Faber, H Ebi, EM Coffee, ...
Cancer cell 23 (1), 121-128, 2013
4042013
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ...
Nature medicine 25 (9), 1415-1421, 2019
3992019
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for …
Z Piotrowska, H Isozaki, JK Lennerz, JF Gainor, IT Lennes, VW Zhu, ...
Cancer discovery 8 (12), 1529-1539, 2018
3792018
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy
R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ...
Cell 158 (3), 564-578, 2014
3772014
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ...
PloS one 6 (3), e17948, 2011
3552011
The system can't perform the operation now. Try again later.
Articles 1–20